Three more I-Mab execs exit after US/China operations split
02 Apr 2024
Executive Change
As I-Mab Biopharma embarks on its next chapter as a fully US-based company, it’s parting ways with more executives from the old era.
Chief Business Officer Weimin Tang, Chief Communications Officer Gigi Qi Feng and Chief Legal Officer Richard Cheng Li have resigned from their respective positions, effective March 31, I-Mab disclosed in an SEC filing. “None of these resignations were due to any disagreement with the Company,” it wrote, adding that it’s searching for a new chief business officer and chief legal officer.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.